ZIRCON Phase III Kidney Cancer Imaging Study Completes Target Enrolment MELBOURNE, Australia, March 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, “Telix”, the “Company”) today announces that ZIRCON (Zirconium in Renal Cancer Oncology,...

First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product in Turkey MELBOURNE, Australia and ISTANBUL, Turkey, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) and Eczacıbaşı-Monrol Nuclear Products Co. (‘Eczacıbaşı...

First Patient Dosed in Phase I/II Trial of Renal Cancer Imaging Product in Japan TOKYO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Japan K.K., a wholly-owned subsidiary of Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that...

Telix and Isologic conclude manufacturing agreement for North America MELBOURNE, Australia and MONTREAL, June 25, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix Group”, the “Company”), a clinical-stage biopharmaceutical company focused on the...

Telix Pharmaceuticals Appointed Dr. Bernard Lambert as President of Telix Pharmaceuticals (US) Inc. MELBOURNE, Australia and INDIANAPOLIS, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the...